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Abstract Metastatic colorectal carcinomas (CRC) resistant
to chemotherapy may benefit from targeting monoclonal
therapy cetuximab when they express the epidermal growth
factor receptor (EGFR). Because of its clinical implications,
we studied EGFR expression by immunohistochemistry on
tissue sections of primary CRC (n=32) and their related
metastases (n=53). A tissue microarray (TMA) was
generated from the same paraffin blocks to determine
whether this technique could be used for EGFR screening
in CRC. On tissue sections, 84% of the primary CRC and
94% of the metastases were EGFR-positive. When
matched, they showed a concordant EGFR-positive status
in 78% of the cases. Moreover, staining intensity and extent
of EGFR-positive cells in the primary CRC correlated with
those observed in the synchronous metastases. On TMA,
65% of the primary CRC, 66% of the metastases, and 43%
of the matched primary CRC metastases were EGFR-
positive. There was no concordant EGFR status between
the primary and the metastatic sites. A strong discrepancy
of EGFR status was noted between TMA and tissue
sections. In conclusion, EGFR expression measured in
tissue sections from primary CRC and their related
metastases was found to be similar and frequent, but it
was significantly underestimated by the TMA technique.
Keywords Epidermalgrowth factorreceptor.Colorectal
carcinoma.Metastases.Tissuemicroarray
Introduction
Epidermal growth factor receptor (EGFR), also called
HER1, is a member of the transmembrane tyrosine kinase
receptor family. In normal and malignant cells, the
activation of EGFR receptor cascades has multiple con-
sequences, such as cell growth, differentiation, and prolif-
eration [10]. The EGFR signaling pathway may also
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static dissemination [10]. To block the activation of this
receptor, targeted therapies have been developed, represent-
ing a new and promising strategy for cancer management
[15]. Thus, antibodies directed against EGFR have recently
been integrated into the treatment of metastatic colorectal
carcinomas (CRC) resistant to chemotherapy [3, 23]. Such
a strategy requires an EGFR immunohistochemical assess-
ment by the pathologist to ensure that the targeted receptor
is present in the tumor. Cancer patients included in these
protocols are not always treated in the same institute for
their primary disease and for their metastatic disease.
Moreover, metastases are not always available for histolo-
gy. It is thus possible that EGFR expression be evaluated in
only one of the tumor locations (i.e., primary or metastatic).
However, few and controversial data are available
concerning the EGFR status in its primary site and the
related metastatic sites [6, 11, 13, 24].
The first goal of our study was to analyze whether EFGR
expression in colorectal primary tumors and their metastatic
sites was similar or not. To answer this question, formalin-
fixed and paraffin-embedded primary CRC from 32 patients
and their related synchronous metastases (n=45) were
examined using a standardized EGFR immunohistochemi-
cal procedure. Additionally, metachronous metastases (n=8)
from four out of 32 patients were also processed for EGFR
immunohistochemistry.
The second goal of this study was to evaluate EGFR
expression on a tissue microarray (TMA) generated from
the same paraffin blocks and to compare these results with
those obtained by using the whole tissue sections. This
comparison was carried out to determine whether the
increasingly used TMA technology is a reliable tool for
high-throughput EGFR screening in CRC [17, 26].
Materials and methods
Patient characteristics
Clinical and histopathological characteristics of the patients
are reported in Table 1. Thirty-two patients, having
undergone surgical resection of both the primary tumor
and the corresponding metastatic sites in our institution
between 2000 and 2004, were selected from a pathological
database of colorectal cancer cases. There were 15 men
(47%) and 17 women (53%). Median age at surgery was
60 years (ranging from 45 to 81 years). Twenty-one patients
(66%) had colon cancer and 11 (34%) had rectal cancer.
The most common histological type was adenocarcinoma
(91%), the remaining three cases (9%) being mucinous
carcinomas. According to the latest TNM classification
[28], all the patients had stage-IV disease because of
synchronous metastases at the time of diagnosis. Among
them, four patients received neoadjuvant radiotherapy (n=2)
or radiochemotherapy (n=2) for rectal carcinomas and six
others received neoadjuvant chemotherapy before surgical
resection of their metastases. Eighty-five paraffin-embed-
ded tumor samples from CRC (n=32) and liver, pulmonary,
and ovarian metastases (n=51, 1, and 1, respectively) were
available. Synchronous metastases (n=45) were unique in
23 patients and multiple (n=22) in nine patients, consisting
of two, three, or four locations in the liver (Table 1).
Metachronous metastases (n=8) from four patients were
also collected and assessed for EGFR immunohistochem-
istry. They consisted of five multiple liver metastases for
one patient, one single liver metastasis for two patients, and
one pulmonary metastasis for one patient. Synchronous and
metachronous metastases were obtained by metastasec-
tomy. All resected samples were received fresh, then
immediately fixed in 10% pH neutral formalin for 48 h
and embedded in paraffin before processing.
EGFR immunohistochemistry
EGFR immunohistochemistry was carried out on freshly
sectioned tissue slides which has been shown to be critical
for optimal EGFR immunoreactivity [1]. Immunohisto-
chemistry of the tumors was performed by using the Dako
autostainer and the EGFR pharmDx™ kit (K1494, Dako,
Glostrup, Denmark), according to the manufacturer’s
instructions. Briefly, 4-μm-thick sections were mounted
on silanized slides and allowed to dry overnight at 37°C.
After deparaffinization and rehydratation, slides were
incubated with 3% hydrogen peroxide for 5 min. After
washing with the supplied buffer, tissue sections were
covered for 5 min with a proteinase K solution. The slides
were then incubated for 30 min with the primary mouse
anti-EGFR monoclonal antibody (clone 2-18C9), which
binds to a formalin-resistant epitope near the ligand-binding
site on the extracellular domain of EGFR. After two rinses
in buffer, the slides were incubated with a horseradish
peroxidase-labeled polymer coupled to secondary anti-
bodies for 30 min. Tissue staining was visualized with
diaminobenzidine as substrate-chromogen solution. Slides
were counterstained with hematoxylin, dehydrated, and
mounted. Negative control sections were processed without
the primary antibody but with an irrelevant murine IgG1
supplied with the kit. Negative and positive control cell
slides (CAMA-1 and HT29 cell lines, respectively),
provided with the EGFR pharmDx™ kit, were also used
to ensure that each assay run was performed appropriately
and according to protocol specifications. Furthermore,
perineurium and normal mucosae on primary CRC and
hepatocytes surrounding the metastases were considered as
positive internal controls on tumor slides.
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Tissue blocks appearing to have enough material upon
gross inspection were initially selected and hematoxylin–
eosin-stained sections were evaluated by two observers
(F. Bibeau and F. Boissière-Michot) for the presence of
carcinoma. The areas to be used for the construction of
the TMAs were marked on the slide and the donor block.
Particular attention was made to select invasive cells near
the tumor front. The tissues corresponding to selected
areas were sampled using a manual arraying instrument
(Manual Tissue Arrayer 1, Beecher Instruments, Sun
Prairie, WI, USA). Two TMAs were constructed using
0.6-mm tissue cores. The sampling consisted of three
malignant cores from different areas of the tumor from a
single case of invasive colorectal cancer, placed at
specified coordinates. When possible, normal mucosa
was also sampled as internal control. After the arraying
Table 1 Clinical data and EGFR status among primary CRC and their related metastases
Clinical data EGFR status
a on tissue sections
Case no. Sex Age (years) pTNM Location Neoadjuvant treatment Primary site Synchronous
metastases
(location number)
Metachronous
metastases
(location number)
12341 23 4 5
1 M 60 T3N1M1 C + ++++
2 M 60 T3N2M1 R RCT + + + +
3 M 66 T2N0M1 R + + + +
4 M 49 T3N2M1 R CT + + + + + + + +
5 M 70 T3N1M1 C + + +
6 F 74 T3N1M1 R RCT + + +
7 F 59 T3N2M1 R CT + + + −
8 M 71 T3N2M1 C + + +
9 F 55 T3N2M1 R − + −
10 F 61 T4N1M1 C CT + + +
11 F 68 T3N1M1 C CT + + +
12 M 75 T3N1M1 R + +
13 M 72 T3N1M1 C + +
14 M 54 T3N0M1 C + +
15 F 55 T4N1M1 C + +
16 F 57 T4N2M1 C + +
17 F 52 T3N1M1 R + +
18 M 53 T3N0M1 C + +
19 M 62 T4N2M1 C + +
20 F 77 T3N2M1 C + +
21 F 49 T3N1M1 C + +
22 F 51 T3N2M1 C + +
23 M 62 T3N2M1 R RT + +
24 F 65 T3N1M1 C CT + +
25 M 56 T4N1M1 C CT + +
26 F 47 T3N1M1 R RT + +
27 F 59 T3N1M1 C + −
28 F 45 T3N2M1 C + −
29 F 81 T3N1M1 R − +
30 M 58 T2N0M1 C − +
31 M 69 T3N1M1 C − +
32 F 68 T3N2M1 C − +
Liver metastases in all cases except for a metachronous pulmonary metastasis and a synchronous ovarian metastasis in patients 7 and 15,
respectively
C colon, R rectum, RCT radio-chemotherapy, CT chemotherapy before surgical resection of metastasis, RT radiotherapy
aPositive if >1% of tumor cells expressed EGFR
Virchows Arch (2006) 449:281–287 283was completed, TMA blocks were sectioned at a
thickness of 4 μm. One section was stained with
hematoxylin–eosin, and EGFR immunostaining using the
immunohistochemical system kit EGFR pharmDx™ was
performed on the adjacent section. Among the 32 cases
sampled, 31 primary CRC, 29 metastatic sites, and 28
matched sites were assessable with this technology.
EGFR immunohistochemical staining scoring system
EGFR assessment was realized according to the EGFR
pharmDx™ scoring guidelines. EGFR expression was
evaluated on sections including the deepest region of tumor
invasion as this region was shown to contain the greatest
density of EGFR-positive cells [6]. Results were reported as
positive when a complete or incomplete circumferential
membrane staining was observed in at least 1% of the
tumor cells. Staining was defined as immunostaining of
tumor cell membranes above background level and scored
as follows: 1+=weak, 2+=moderate, and 3+=strong. The
absence of membrane staining or cytoplasmic staining was
reported as negative. The percentage of stained cells was
assessed as follows: 1–10, 10–50, and >50%. Slides were
scored by two pathologists (F. Bibeau and J.C. Sabourin),
who were blinded to the patients’ characteristics. In the case
of disagreement (three out of 91 specimens), the EGFR
status was determined by consensus after simultaneous dual
reexamination.
In addition to these standardized criteria, a semiquan-
titative analysis was performed taking into account both
the staining intensity and the percentage of positive
tumor cells.
Statistical analysis
The cut-off value for negative/positive expression of EGFR
was 1% of tumor cells displaying a membranous staining,
as specified by the EGFR pharmDx™ scoring guidelines.
Data were summarized by frequency and percentage for
categorical variables and by means, standard deviations,
median, and range for continuous variables. For TMA
analysis, the percentage of positive cells was calculated
from the mean of triple cores.
The correlation between the percentage of positive
cells observed on primary tumors and matched metasta-
ses was evaluated with the Spearman correlation
coefficient. Associations between categorical variables
were examined using McNemar’s chi2 test. A P value of
less than 0.05 was considered statistically significant. Due
to the small number of patients with metachronous
metastases, only the correlation between the matched
primary CRC and the synchronous metastatic sites was
made.
Results
EGFR expression of primary CRC and their related
metastases on tissue sections
EGFR reactivity was not homogeneous throughout the
tumors. EGFR immunostaining was mainly observed in the
deepest region of the primary CRC or at the periphery of
metastases, especially in the liver. Of note, EGFR immu-
noreactivity was often greater in isolated tumor cells and in
small clusters of tumor cells.
Eighty-four percent of primary CRC (27 out of 32) and
94% of the synchronous metastases (30 out of 32)
displayed EGFR reactivity in more than 1% of the tumor
cells (Table 1). Overall, all patients displayed an EGFR-
positive status considering EGFR-expression in the primary
tumor and/or the metastatic sites. EGFR expression was
positive at both sites in most of the cases (25 out of 32;
78%) and rarely in only one site, i.e., primitive (two out of
32; 6%) or metastastic (five out of 32; 16%). However, the
discordant cases (i.e., positive primary sites with negative
metastasis and conversely) were not statistically significant
(P=0.453).
Nine (28%), 10 (31%), and eight (25%) of the primary
CRC and seven (22%), 14 (44%), and nine (28%) of the
synchronous metastases displayed a weak, moderate, and
strong positivity, respectively. According to the extent of
EGFR immunoreactivity, five (16%) primary CRC had no
reactivity, 12 (37.5%) had <10% reactive cells, eight (25%)
had >10–50% positive cells, and seven (22%) had >50%
labeled cells. In the synchronous metastases, two cases
(6%) were negative, 13 (41%) had <10% reactive cells, 11
(34%) had >10–50% positive cells, and six (19%) had
>50% labeled cells.
Interestingly, the percentage of EGFR-positive tumor
cells in the primary site was significantly correlated with
that observed in the synchronous metastases (r
2=0.616,
P=0.0002). This correlation was also demonstrated when
combining EGFR scoring (labeling intensity) with the
percentage of EGFR-positive tumor cells (r
2=0.559,
P=0.0009). One example of the pattern of EGFR labeling
in both sites is shown in Fig. 1. EGFR expression was
positive among the multiple synchronous liver metastases
in eight out of nine patients (i.e., 21 out of 22 samples,
Table 1). The related primary site of the discordant case
(two synchronous metastases: one was EGFR-positive, the
other was EGFR-negative) displayed an EGFR-negative
status (case number 9, Table 1).
Regarding the analysis of EGFR expression in meta-
chronous metastases, we observed an analogous EGFR-
positive status between all the available liver metastases
(i.e., five metastases for one patient, one metastasis for two
patients) and their related primary sites and synchronous
284 Virchows Arch (2006) 449:281–287metastases (case numbers 4, 10, and 11, Table 1). The only
metachronous pulmonary metastasis available for analysis
did not show any EGFR immunoreactivity, whereas both
the corresponding hepatic synchronous metastases and the
primary site expressed EGFR (case number 7, Table 1).
EGFR expression of primary CRC and their related
metastases on TMA
On the first TMA block, the EGFR status was found to be
positive in 18 out of the 31 (58%) assessable primary
tumors and 18 out of 29 metastases (62%) (Table 2). Only
nine out of 28 (32%) assessable matched tumors were
positive for both the primary and the metastatic sites,
whereas four out of 28 (14%) were negative. Fifteen out of
28 (54%) cases were discordant (i.e., seven positive
primary and negative metastases, and eight, conversely).
On the second TMA block, 14 out of 31 (45%) primary
tumors and 16 out of 29 (55%) metastases were EGFR-
positive (Table 2). Eight out of 28 (29%) assessable
matched tumors were positive for both sites, whereas nine
(32%) were negative. Eleven out of 28 cases (39%) were
discordant (i.e., four positive primary sites and negative
metastases, and seven, conversely).
When combining the two TMAs (six tissue cores), the
number of positive cases increased, to reach 20 out of 31 of
the primary tumors (65%) and 19 out of 29 of the
metastases (66%) (Table 2). Twelve out of 28 (43%)
assessable matched tumors were positive for both sites,
whereas three (11%) were negative. Nevertheless, 13 cases
(46%) remained discordant (i.e., six positive primary and
negative metastases, and seven, conversely). Moreover,
using the TMA technology and whatever the number of
cores (three or six), we failed to demonstrate any
correlation of EGFR expression between primitive sites
and matched metastases.
Comparison of EGFR expression between tissue sections
and TMA
The EGFR status on the triple core-tissue array was
significantly underestimated at both sites when compared
with tissue sections (P=0.011 for both primitive and
metastatic sites for the first TMA; P=0.0005 and
P=0.0023 for primitive and metastatic sites, respectively,
for the second TMA). When combining both TMAs (six
tissue cores), although the number of positive cases
increased, we still observed a significant discrepancy
between both techniques for primitive sites (P=0.034) and
metastases (P=0.0001).
Discussion
EGFR is a 170-kDa transmembrane cell surface receptor
encoded by the human HER1 gene, which promotes
malignant cell proliferation and cancer progression [15].
Interfering with EGFR cell signaling by targeting strategies
represents a novel approach to the treatment of solid tumors
[15]. Among them, cetuximab (Erbitux®), a chimeric
monoclonal human–mouse antibody, is used for the
treatment of EGFR-expressing metastatic CRC that have
progressed following chemotherapy [3, 23]. To identify
patients eligible for this treatment, an immunohistochemical
evaluation of EGFR expression is required. Although
numerous studies have demonstrated EGFR expression in
70–97% of CRC [4, 6, 29], only few and controversial data
are available on the EGFR status in distant metastases [6,
11, 13, 24]. Consequently, knowledge of EGFR metastastic
status could be of potential value for therapeutic decisions,
particularly if it differs from the primary tumors.
Fig. 1 Example of EGFR ex-
pression in tissue sections in a
primary colorectal carcinoma (a)
and the matched metastasis (b).
Strong membranous staining of
numerous cells in both sites
(immunoperoxidase; bar 50 μm)
Table 2 Comparison of EGFR expression in primary CRC and their
synchronous metastatic sites on whole tissue sections and TMA
Primary site Metastases Matched sites
Tissue sections 27/32 (84%) 30/32 (94%) 25/32 (78%)
First TMA 18/31 (58%) 18/29 (62%) 9/28 (32%)
Second TMA 14/31 (45%) 16/29 (55%) 8/28 (29%)
Both TMAs 20/31 (65%) 19/29 (66%) 12/28 (43%)
Data are expressed as the number of positive cases/total number of
specimens
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is similar in different tumor sites, we compared the EGFR
status of a set of primary CRC and their corresponding
synchronous distant metastases, using a standardized
immunohistochemistry test (EGFR pharmDx™, Dako).
We also analyzed EGFR expression in metachronous
metastases, when available, to study possible changes of
EGFR expression during the metastatic process of CRC.
On whole tissue sections, our results demonstrated that
EGFR expression was frequent and similar in both the
primary and the metastatic sites. In our study, immunoreac-
tivity was observed in 84 and 94% of the primary tumors and
the metastases, respectively (Table 1). The 32 matched
primary and synchronous metastatic CRC expressed a
concordant EGFR status in 78% of the cases, all immuno-
positive, and the discordant cases were not statistically
significant (P=0.453). Our data are in agreement with three
recent studies that showed a high frequency and concordance
of EGFR expression in matched primary tumors and distant
metastatic lesions of CRC [8, 11, 13]. To our knowledge,
only one study reported no correlation of EGFR expression
on primary CRC and related metastases [24].
In addition to the concordant EGFR status between
primary and metastatic locations, our study showed that
both the staining intensity and the percentage of EGFR-
positive cells in the primary site were significantly
correlated with those observed in synchronous metastases
(Fig. 1). Our work also emphasized the EGFR-positive
status among multiple synchronous and metachronous
metastatic sites in most of the patients (Table 1). Further-
more, we noticed an analogous EGFR-positive status
between all metachronous metastases but one, their
related synchronous metastases, and their primary CRC
(Table 1). Such data, to our knowledge, have never been
reported in clinical samples and seem to agree with the
preclinical results, suggesting that EGFR expression is
required for the tumor to acquire metastatic potential [19,
22, 27]. Moreover, in our cohort, all the patients displayed
an EGFR-positive status. This would mean that most of the
patients are potentially eligible for therapy with EGFR-
targeted monoclonal antibodies, given the results of the
immunohistochemistry.
The clinical relevance of EGFR immunohistochemical
detection is today a matter of debate because EGFR-
negative patients might respond to cetuximab and EGFR-
positive patients might not [2, 3, 5, 23]. One reason
proposed to explain this lack of correlation is a possible
difference in the EGFR status between the primary tumor
and the metastatic sites [24]. Our results do not support this
hypothesis. The lack of response in EGFR-positive patients
could more likely be explained by alterations in the critical
downstream signals, activated via other receptors or other
pathways. It is also plausible that the lack of correlation
between EGFR expression and antitumor activity could be
due to the potential for cetuximab to induce antibody-
dependent cell-mediated cytotoxicity and to the absence of
discrimination between the high- and low-affinity receptors
with the commonly used antibodies [2, 14, 16]. Moreover,
negative immunohistochemical results may be linked to the
heterogeneity of EGFR expression and could, in part,
represent false negative cases that might respond to
EGFR-targeted therapy.
The second goal of our study was to perform the same
analysis on TMA generated with the same paraffin blocks
used for EGFR assessment on the whole tissue sections.
TMA has been employed to study the molecular profile of
different cancer types and to test hypotheses regarding
colorectal carcinogenesis and prognosis [9, 12, 20].
However, EGFR expression in primary CRC and their
related metastases has rarely been studied with this
approach and the few published results are controversial
[8, 25]. In our work, TMA was carried on multiple (three)
cores, selected from the deepest region of tumor invasion.
Nevertheless, the results obtained were systematically
lower than those observed on the whole tissue sections.
Even when combining the two TMAs, EGFR positivity
only reached 65 and 66% in primary CRC and their related
metastases, respectively (Table 2). In contrast to what we
observed on tissue sections, we failed to demonstrate a
correlation of EGFR expression between both sites using
the TMA technology. The discordant results between the
two technologies may be explained by cases containing rare
stained cells (i.e., <10%) or small invasive clusters, which
may be not selected when TMA is performed even using
three or six cores. These small tumor clusters, also called
tumor “budding,” belong to a phenomenon which might be
involved in metastatic spreading and seem to represent a
poor prognostic factor [18, 21, 30]. Such data are of
importance because TMA has been recognized as a useful
and powerful tool for screening immunohistochemical
markers for prognostic purposes and for carcinogenesis
studies, as well.
In conclusion, we demonstrated that EGFR expression
on whole tissue sections is frequent and similar in primary
CRC and their related metastases. Our results also indicated
that the EGFR status of the primary is concordant with
those of metastases, whatever the number of sites and the
time of occurrence, i.e., synchronous or metachronous. This
may have clinical implications because patients are not
always treated in the same institute for their primary disease
and for their metastatic disease. In our experience, TMA
does not represent an appropriate technique for EGFR
screening in CRC because it significantly underestimates
EGFR expression and does not provide data similar to those
obtained with whole tissue sections. Undoubtedly, this
technology is a reliable tool for the high-throughput
286 Virchows Arch (2006) 449:281–287assessment of homogeneously distributed proteins [7], but
it appears to generate unreliable information with very
heterogeneous markers such as EGFR.
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